IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Ras-driven cancers, including lung and breast cancer, represent a significant therapeutic challenge.
• Targeting oncogenic Ras signaling is a key strategy for developing novel anti-cancer treatments.

Purpose of the Study:

• To identify and characterize a novel small molecule inhibitor of Ras signaling.
• To evaluate the anti-tumor efficacy and mechanism of action of the identified compound in preclinical cancer models.

Main Methods:

• In silico screening combined with in vitro assays to identify potential inhibitors.
• High-Performance Liquid Chromatography (HPLC) for compound purification and identification.
• Cell proliferation assays (2D and 3D), cell spreading, and lamellipodia formation analysis.
• Xenograft mouse models for in vivo efficacy studies.
• Immunohistochemistry for apoptosis analysis.

Main Results:

• IODVA1 was identified as the active component of NSC124205, a potent inhibitor of Ras-driven cancer cells.
• IODVA1 significantly reduced cell proliferation, spreading, and lamellipodia formation by downregulating Rac activity.
• In vivo studies demonstrated significant impairment of xenograft tumor growth in Ras-driven cancers with no observable toxicity.
• Tumor sections indicated that cell death was mediated by increased apoptosis.

Conclusions:

• IODVA1 effectively targets Rac signaling to induce apoptosis in Ras-transformed cells.
• IODVA1 demonstrates significant anti-tumor activity in preclinical models of Ras-driven lung and breast cancers.
• IODVA1 holds considerable promise as a potential therapeutic agent for Ras-driven malignancies.